Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

BACKGROUND: In the existing next generation sequencing (NGS) system, epidermal growth factor receptor (EGFR) exon 19 deletion-insertion (19delins) is still interpreted into the category of EGFR exon 19 deletion (19del). However, the controversy exists whether the two mutation types have the similar...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yurong, Zheng, Ruipan, Hu, Peizhu, Zhang, Ziheng, Shen, Shujing, Li, Xingya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590339/
https://www.ncbi.nlm.nih.gov/pubmed/34774017
http://dx.doi.org/10.1186/s12885-021-08942-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590339/
https://www.ncbi.nlm.nih.gov/pubmed/34774017
http://dx.doi.org/10.1186/s12885-021-08942-x

Ejemplares similares